PEDIATRICS Vol. 36 No. 5 November 1965, pp. 714-720
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Potter, J. L.
Right arrow Articles by Lemm, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Potter, J. L.
Right arrow Articles by Lemm, J.

COMPLEX FORMATION BETWEEN BASIC ANTIBIOTICS AND DEOXYRIBONUCLEIC ACID IN HUMAN PULMONARY SECRETIONS

Joseph L. Potter M.D., Ph.D.1, LeRoy W. Matthews M.D.1, Samuel Spector M.D.1, and Joy Lemm B.A.1

1 Department of Pediatrics, Babies and Childrens Hospital, Western Reserve University School of Medicine, Cleveland, Ohio

1. Complex formation and precipitation of DNA by neomycin, with consequent inactivation of the antibiotic, has been shown to occur in the pulmonary secretions of patients with cystic fibrosis.

2. Highly polymerized DNA from a variety of sources, as well as two samples of RNA, were precipitated by neomycin in vitro. Polymixin, kanamycin, colymycin, and streptomycin similarly co-precipitate with DNA in vitro.

3. The minimum chain length of polynucleotide required for precipitation in the DNA-neomycin system was 10.

4. The complex is readily attacked by DNase I resulting in the splitting of the DNA and the liberation of the antibiotic. Both components of the complex are solubilized in M sodium chloride.

5. The resistance of purulent foci of infection to therapy with basic antimicrobial agents may, in part, be due to the complex formation with the high levels of DNA found at the site of infection.

Submitted on March 19, 1965
Accepted on May 12, 1965




This article has been cited by other articles:


Home page
 ChestHome page
S. B. Fiel
History and Evolution of Aerosolized Therapeutics : Overview and Introduction
Chest, September 1, 2001; 120(3_suppl): 87S - 88S.
[Full Text] [PDF]

Home page
 ChestHome page
P. W. Campbell III and L. Saiman
Use of Aerosolized Antibiotics in Patients With Cystic Fibrosis
Chest, September 1, 1999; 116(3): 775 - 788.
[Full Text] [PDF]